{"product_id":"first-wave-biopharma-inc-fwbi-financial-and-strategic-swot-analysis-review","title":"First Wave BioPharma Inc (FWBI) - Financial and Strategic SWOT Analysis Review","description":"\u003cp\u003eFirst Wave BioPharma Inc (FWBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.\u003cbr\u003e\nThe profile contains critical company information including:Business description – A detailed description of the company’s operations and business divisions.Corporate strategy – Analyst’s summarization of the company’s business strategy.SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.Company history – Progression of key events associated with the company.Major products and services – A list of major products, services and brands of the company.Key competitors – A list of key competitors to the company.Key employees – A list of the key executives of the company.Executive biographies – A brief summary of the executives’ employment history.Key operational heads – A list of personnel heading key departments\/functions.Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly\/semi-annual financial statements published by the company for 5 interims history.Highlights\u003c\/p\u003e\n\n\u003cp\u003eFirst Wave BioPharma Inc (First Wave BioPharma), formerly AzurRx BioPharma Inc, is a development-stage biopharmaceutical company that focuses on non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company's products under development include MS1819 a non-systemic yeast recombinant enzyme intended for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). Its pre-clinical products include AZX1103 and AZX1101 which is a recombinant beta-lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections and antibiotic-associated diarrhea. The company has operations in France and the US. First Wave BioPharma is headquartered in Brooklyn, New York, the US.\u003c\/p\u003e\n\n\u003cp\u003eFirst Wave BioPharma Inc Key Recent Developments\u003c\/p\u003e\n\n\u003cp\u003eJan 30,2023: First Wave BioPharma to Present at the BIO CEO \u0026amp; Investor Conference\u003cbr\u003e\nJan 24,2023: First Wave BioPharma to present at Sequire Biotechnology Conference\u003cbr\u003e\nSep 28,2022: First Wave BioPharma’s CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference\u003cbr\u003e\nAug 29,2022: First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022\u003c\/p\u003e\n\n\u003cp\u003eKey benefits of buying this profile include:\u003c\/p\u003e\n\n\u003cp\u003eYou get detailed information about the company and its operations to identify potential customers and suppliers.\u003cbr\u003e\nThe profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.\u003c\/p\u003e\n\n\u003cp\u003eUnderstand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.\u003cbr\u003e\nThe company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.\u003c\/p\u003e\n\n\u003cp\u003eEquip yourself with information that enables you to sharpen your strategies and transform your operations profitably.\u003cbr\u003e\nOpportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and\/or technological threats are highlighted.\u003c\/p\u003e\n\n\u003cp\u003eScout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.\u003cbr\u003e\nFinancial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.\u003c\/p\u003e\n\n\u003cp\u003eGain key insights into the company for academic or business research.\u003cbr\u003e\nKey elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.\u003c\/p\u003e\n\n\u003cp\u003eNote:Some sections may be missing if data is unavailable for the company\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"August, 2023 \/ 45 Pages \/ MCW16231930","offer_id":47647419171122,"sku":null,"price":150.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/first-wave-biopharma-inc-fwbi-financial-and-strategic-swot-analysis-review","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}